Who are Standard dose of TNFi's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Switch to a second anti-TNF drug alone, ETN+MTX, Etanercept (ETN), Etanercept via Autoinjector B, Reduced doses of anti-TNF, Etanercept + Acitretin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/standard-dose-of-tnfi.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Standard dose of TNFi — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Standard dose of TNFi (Standard dose of TNFi) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: TNF inhibitor. Area: Immunology.

marketed TNF inhibitor TNF-α (tumor necrosis factor-alpha) Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Standard dose of TNFi (Standard dose of TNFi) — University Health Network, Toronto. TNF inhibitors block tumor necrosis factor (TNF), a key inflammatory cytokine that drives immune-mediated inflammation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Standard dose of TNFi TARGET	Standard dose of TNFi	University Health Network, Toronto	marketed	TNF inhibitor	TNF-α (tumor necrosis factor-alpha)
Switch to a second anti-TNF drug alone	Switch to a second anti-TNF drug alone	Védrines, Philippe, M.D.	marketed	TNF inhibitor (class-level; specific agent varies)	TNF-alpha
ETN+MTX	ETN+MTX	Japan Biological Agent Study Integrated Consortium	marketed	TNF inhibitor + DMARD combination	TNF-α receptor; dihydrofolate reductase
Etanercept (ETN)	Etanercept (ETN)	University of Leeds	marketed	TNF inhibitor (TNF receptor fusion protein)	TNF-alpha (TNF) and TNF-beta (lymphotoxin-alpha)
Etanercept via Autoinjector B	Etanercept via Autoinjector B	Amgen	marketed	TNF inhibitor (TNF receptor fusion protein)	TNF-α and TNF-β
Reduced doses of anti-TNF	Reduced doses of anti-TNF	Spanish Clinical Pharmacology Society	marketed	TNF inhibitor	TNF-α (Tumor Necrosis Factor-alpha)
Etanercept + Acitretin	Etanercept + Acitretin	Pfizer	marketed	TNF inhibitor + retinoid combination	TNF-α receptor (p75/p55) + retinoid X receptor (RXR) and retinoic acid receptor (RAR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (TNF inhibitor class)

University Hospital, Montpellier · 2 drugs in this class
Amgen · 1 drug in this class
Biogen · 1 drug in this class
Centre Hospitalier Universitaire de Saint Etienne · 1 drug in this class
National Eye Institute (NEI) · 1 drug in this class
Abbott · 1 drug in this class
Spanish Clinical Pharmacology Society · 1 drug in this class
Takeda · 1 drug in this class
University Health Network, Toronto · 1 drug in this class
University Hospital, Ghent · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Standard dose of TNFi — Competitive Intelligence Brief. https://druglandscape.com/ci/standard-dose-of-tnfi. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab